News

September 1, 2016: BioSculpture Technology, Inc. has a qualifed tier 2 Regulation A Offering to commercialize its patented minimally invasive EVL® device and method for the endoscopic removal of visceral or “belly” fat, as a new treatment of obesity, metabolic syndrome and type 2 Diabetes mellitus. Scientific research has confirmed that excessive visceral fat within the abdominal cavity causes metabolic syndrome and type 2 diabetes, decreasing the quality of human life and shortening the lives of those we love.

http://www.bst-ipo.com/

https://youtu.be/5xC8pvNmMeI